Dementia continues to pose a significant challenge in neuroscience and clinical care, affecting millions worldwide. Early detection is pivotal in slowing disease progression and implementing preventive interventions. Life sciences are increasingly leveraging...
The intersection of artificial intelligence (AI) and pharmaceutical research is transforming drug discovery, clinical trials, and healthcare innovation. Leading technology companies Nvidia, Microsoft, and Google are spearheading this evolution, applying advanced AI...
Artificial intelligence company Anthropic is making a significant move into the life sciences sector with the launch of Claude for Life Sciences, a version of its Claude language model platform tailored for scientific research, drug discovery and regulatory workflows....
Microsoft is reportedly preparing a major update to its Copilot AI assistant that will let it draw on licensed medical content from Harvard Health Publishing when responding to user queries about healthcare. The development signals a strategic shift toward embedding...
Medical imaging company Hyperfine, listed on the Nasdaq as HYPR, has announced the pricing of an underwritten public offering of 14 million shares of its Class A common stock at $1.25 per share, yielding gross proceeds of approximately $17.5 million before...
A panel of independent experts convened by the U.S. Food and Drug Administration (FDA) has recommended against approving GSK’s (GSK.L) blood cancer treatment Blenrep, citing concerns over known ocular side effects. The decision prompted a nearly 5% drop in the British...
A panel of independent experts convened by the U.S. Food and Drug Administration (FDA) has recommended against approving GSK’s (GSK.L) blood cancer treatment Blenrep, citing concerns over known ocular side effects. The decision prompted a nearly 5% drop in the British...
The NHS in England is leading the world as the first healthcare system to introduce a pioneering ‘trojan horse’ therapy for patients with blood cancer, offering the potential to delay disease progression nearly three times longer than current treatment...